BioDuro and Roche Expand Strategic Collaboration to Provide Drug Discovery Services
BEIJING, Apr. 7 /PRNewswire-AsiaNet/ --
BioDuro announced today that they have entered into a strategic partnership with Roche to
support discovery phase research efforts at Roche's global research sites. BioDuro will provide
research services in the areas of
discovery chemistry and biology, which can help to shorten (internal) drug
discovery timelines. This agreement is an expansion of an existing relationship.
Roche has many years of experience in partnering with external companies
to complement its internal drug discovery expertise with external services
and innovation. After extensive evaluation of many companies, Roche selected
BioDuro as a strategic partner for this effort.
"Presently, there is intense competition within the CRO industry for
outsourcing and drug discovery services, and the expectation is that they
will deliver problem solving skills and innovation in both chemistry and
biology," commented Robert Goodnow, Ph.D., Roche's Global Head of Medicinal
Chemistry Outsourcing. "We selected BioDuro due to their demonstrated
excellent performance in synthetic chemistry and ability to deliver
integrated medicinal chemistry services."
"BioDuro is pleased to build upon this existing collaboration and work
closely with the experienced team at Roche to aid in the development of novel
therapeutics. We care deeply about working on projects that will impact the
quality of life worldwide and working with Roche ensures this outcome. Our
partnership demonstrates the strength of our innovative, fully integrated R&D
service platform, and is a true testament to the caliber of scientists that
have joined our team," commented John Oyler, Chief Executive Officer and
co-founder of BioDuro LLC.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's
leading research-focused healthcare groups in the fields of pharmaceuticals
and diagnostics. As the world's biggest biotech company and an innovator of
products and services for the early detection, prevention, diagnosis and
treatment of diseases, the Group contributes on a broad range of fronts to
improving people's health and quality of life. Roche is the world leader in
in-vitro diagnostics and drugs for cancer and transplantation, and is a
market leader in virology. It is also active in other major therapeutic areas
such as autoimmune diseases, inflammatory and metabolic disorders and
diseases of the central nervous system. In 2008, sales by the Pharmaceuticals
Division totalled 36.0 billion Swiss francs ($33.3B US), and the Diagnostics
Division posted sales of 9.7 billion francs ($9.0B US). Roche has R&D
agreements and strategic alliances with numerous partners, including majority
ownership interests in Genentech and Chugai, and invested nearly 9 billion
Swiss francs ($8.3B US) in R&D in 2008. Worldwide, the Group employs about
80,000 people. Additional information is available on the Internet at
About BioDuro
BioDuro is a US-based, fully-integrated, end-to-end, life
science, research services company with a team of 580 in Beijing, China.
BioDuro combines western pharmaceutical company quality and professionalism,
with entrepreneurial, innovative biotech research culture, to leverage its
talented, hard-working scientists. BioDuro's clients are over 40
pharmaceutical and biotechnology companies, including 10 of the top-12.
BioDuro's services span the entire range of drug discovery and development,
from discovery chemistry, discovery biology, early ADMET, DMPK, through
pharmacology and drug safety evaluation.
SOURCE: BioDuro
CONTACT: Sharon Valdettaro, Roche Pharma Partnering,
+41-61-688-96-55,
sharon.valdettaro@roche.com, or
Roche Public Affairs,
Darien E. Wilson,
+1-973-562-2232,
darien_e.wilson@roche.com, both of Roche; or
Ryan Brady, Business Development,
+1-317-331-3029,
ryan.brady@bioduro.com, or
Ling Zhang, Public and Governmental Relations,
+86-139-1077-9022,
ling.zhang@bioduro.com, both of BioDuro
NEWS 
